# Multi-omics integration signatures for assessing treatment efficacy in major depressive disorder - URL: https://alisanburak.com/en/wcp-2026-posterler/ev0326 - Language: en - Last updated: not specified - Page title: Multi-omics integration signatures for assessing treatment efficacy in major depressive disorder | WCP 2026 Summary > A multilevel molecular signature encompassing tryptophan metabolism, inflammatory signaling, oxidative balance, lipid homeostasis, and mitochondrial metabolism… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/ev0326) Bu sayfa, 26. Dünya Psikiyatri Kongresi'nde sunulan çalışmanın yapay zekâ desteğiyle hazırlanmış Türkçe özetidir. Çalışmanın sahibi sunan yazarlardır; atıf için orijinal kaynağa başvurun. EV0326 E-PosterPsikofarmakolojiKohort # Multi-omics integration signatures for assessing treatment efficacy in major depressive disorder MULTI-OMICS INTEGRATION SIGNATURES IN MAJOR DEPRESSIVE DISORDER FOR TREATMENT EFFICACY ASSESSMENT Sunan: Salvador Fernández Arroyo Ülke: Spain Kurum: Eurecat, Centre Tecnològic de Catalunya, Centre for Omic Sciences A multilevel molecular signature encompassing tryptophan metabolism, inflammatory signaling, oxidative balance, lipid homeostasis, and mitochondrial metabolism distinguishes patients with major depressive disorder who respond to treatment from those who do not. Given the limited precision of treatment in major depressive disorder (MDD) and interpatient variability in response, this study aimed to identify clinically meaningful biomarkers of treatment efficacy using a multi-omics approach integrating lipoprotein profiling, inflammatory markers, and metabolomics. As part of the OPADE project, 30 patients diagnosed with MDD (N=30) were enrolled, and blood samples were collected at enrollment (baseline) and at 4, 6, and 12 months after treatment initiation. Depression severity and treatment response were assessed using the Hamilton scale; inflammatory markers (cytokines, interleukins, and growth factors) were measured using multiplex bead-based kits, lipoprotein profiles were assessed using 1H-NMR, and metabolomic analysis was performed using LC-QqQ-MS, covering tryptophan-derived neurotransmitters and intermediates, acylcarnitine profiles, and nucleotides. Responders and nonresponders were compared using sPLS-DA. Responders had higher relative levels of metabolites associated with tryptophan catabolism: serotonin, indole-3-acetic acid, tryptamine, 5-hydroxyindole-3-acetic acid, kynurenine, and 3-hydroxykynurenine; uric acid, IL-8, MCP-1, and the acylcarnitines C5:0 and C4:0-2M were also higher. Conversely, responders had lower levels of TNF-alpha, HDL cholesterol, and HDL particle concentrations, as well as less pronounced reductions in TNF-beta, IFN-gamma, IL-4, and melatonin. The authors noted that the kynurenine and 3-hydroxykynurenine findings suggest that treatment response may be explained by a redistribution of tryptophan flux among the serotonergic, microbial indole, and kynurenine pathways rather than by suppression of the kynurenine pathway. They also noted that the lower TNF-alpha signal in responders was consistent with previous evidence showing reductions in inflammatory mediators with successful antidepressant treatment. In conclusion, the study emphasized that treatment response in severe depression is associated not with a single biochemical pathway but with an integrated metabolic and immunological phenotype, and that serotonergic, kynurenine-derived, and indole-derived metabolites support the central role of tryptophan flux. [Orijinal postere git](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2100) Bu çalışmaya nasıl atıf yapılır? APA 7: Samarra, I., Foguet, E., Gavira, J. M. B., Palacios, H., Rodríguez, M. Á., Maestre, A., Frigola-Capell, E., Canela, N., & Arroyo, S. F. (2026, September 23-26). Multi-omics integration signatures in major depressive disorder for treatment efficacy assessment [E-poster]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2100 Vancouver: Samarra I, Foguet E, Gavira JMB, Palacios H, Rodríguez MÁ, Maestre A, et al. Multi-omics integration signatures in major depressive disorder for treatment efficacy assessment [e-poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2100 Yazar adları ve başlık biçimi kongre sisteminden otomatik oluşturulmuştur; kullanmadan önce orijinal posterle karşılaştırın. ## Aynı konudan - [Açığı kapatmak: erişkin DEHB ilacı başlanmadan önce EKG sevk uyumunun iyileştirilmesi, kapalı döngü klinik denetim](https://alisanburak.com/en/wcp-2026-posterler/ev0088) - [Anksiyete bozukluğu olan hastalarda psikobiyotik müdahalesi: ısıl işlem görmüş Lactobacillus paracasei PS23'ün etkilerini inceleyen çift kör randomize kontrollü çalışma](https://alisanburak.com/en/wcp-2026-posterler/ev0126) - [Otizm spektrum bozukluğunda bumetanidin tedavi edici potansiyeli: güncel kanıtlar ve gelecek yönelimleri](https://alisanburak.com/en/wcp-2026-posterler/ev0157) - [Verbaskozid ile otizm spektrum bozukluğu tedavisinin mekanizmaları: ağ farmakolojisi, moleküler yerleştirme ve moleküler dinamik temelli inceleme](https://alisanburak.com/en/wcp-2026-posterler/ev0172) - [Otizm spektrum bozukluğunun çekirdek belirtilerinin tedavisinde kannabidiol: sistematik derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0186) [Tüm WCP 2026 özetleri](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/ev0326 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim